Alzheimer Prevention Trials (APT) Webstudy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03638583|
Recruitment Status : Recruiting
First Posted : August 20, 2018
Last Update Posted : October 21, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease|
|Alzheimer Disease Dementia|
The APT Webstudy will use web-based cognitive testing and questionnaires to generate a risk score which will be used to identify individuals who may be at an increased risk for developing AD dementia.
Individuals who join the APT Webstudy will register at https://www.aptwebstudy.org/, sign an electronic informed consent form (ICF), provide basic demographic information and participate in web-based cognitive testing. Participants will return the APT Webstudy quarterly (every 3 months) to complete the cognitive testing again.
Based on the risk score and changes identified in the cognitive testing results, participants will be invited to visit a partnering clinical trial site for an in-person visit with biomarker testing and clinical assessment.
The combined results of the web-based assessments, with the biomarker and clinical assessments, will allow an adaptive statistical algorithm to improve the selection of those at highest risk for developing AD.
To Join the APT Webstudy, please visit https://www.aptwebstudy.org/.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||200000 participants|
|Target Follow-Up Duration:||5 Years|
|Official Title:||Alzheimer Prevention Trials (APT) Webstudy|
|Actual Study Start Date :||December 20, 2017|
|Estimated Primary Completion Date :||April 30, 2023|
|Estimated Study Completion Date :||April 30, 2023|
- Enrollment into Alzheimer's prevention research studies [ Time Frame: 5 years ]
- Referral into prevention research studies [ Time Frame: 5 years ]
- Number of individuals enrolled into Alzheimer's prevention studies [ Time Frame: 5 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||50 Years to 85 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
|Sampling Method:||Non-Probability Sample|
- male or female at least 50 years of age
- no evidence of dementia
- willing to participate in remote longitudinal cognitive testing and possible referral for biomarker assessment based on risk
- N/A. Anyone can register for the APT Webstudy, however, only individuals identified using the risk algorithm will be referred for in-person biomarker assessments.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03638583
|Contact: APT Webstudy Teamemail@example.com|
|United States, California|
|San Diego, California, United States, 92121|
|Contact: APT Webstudy Team 858-877-3135 firstname.lastname@example.org|
|Principal Investigator:||Paul Aisen, MD||USC ATRI|
|Principal Investigator:||Reisa Sperling, MD||Brigham and Women's Hospital|
|Principal Investigator:||Jeffrey Cummings, MD||The Cleveland Clinic|
|Responsible Party:||Paul Aisen, Professor, University of Southern California|
|Other Study ID Numbers:||
R01AG053798 ( U.S. NIH Grant/Contract )
|First Posted:||August 20, 2018 Key Record Dates|
|Last Update Posted:||October 21, 2022|
|Last Verified:||October 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Central Nervous System Diseases
Nervous System Diseases